BioAge Labs to Present on Therapeutics for Brain Aging Targeting NLRP3, Apelin, and Other Novel Pathways

BioAge Labs, a privately held clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that the company will provide updates on the company’s progress in novel target identification and drug development in the brain aging area at upcoming conferences in the US and UK.

“Brain aging can lead to devastating neurological conditions, which affect millions of people every year,” said Kristen Fortney, PhD, CEO and co-founder of BioAge. “Our discovery platform reveals biological drivers of cognitive decline that could be targeted with novel therapeutics to prevent, slow, or reverse neurodegeneration across the full continuum of disease, from early stages to established dementias. We are excited to share our innovative clinical vision and strategies with partners and investors at leading conferences this quarter.”

The BioAge platform has implicated multiple mechanisms in brain aging, including chronic activation of the NLRP3 inflammasome and declining apelin pathway activity. BioAge is developing a novel class of CNS-penetrant NLRP3 inhibitors for neurodegenerative and neurosensory disorders associated with aging, and its apelin receptor agonist BGE-105 for multiple indications. BioAge will present on these programs at the following events:

• 9th Annual LSX World Congress; London, UK; May 3
• Keystone Symposium on “Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development”; Whistler, BC; May 15–19
• 5th Age-related Disease Therapeutics Summit, San Francisco, June 2
• BIO International Convention; Boston, MA, June 7

“BioAge is deeply rooted in human biology and data, enabling us to uncover diverse strategies for promoting healthy aging and preventing age-related diseases,” said BioAge CBO and Head of Brain Aging Peng Leong PhD, MBA. “Our mission of understanding the mechanisms of brain aging enables us to pursue the development of therapies with far-reaching potential and impact.”